We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Leidos
LDOS
$17.5B
| $40.7M | 0.09% |
387,823
+147,253
| +61% | +$15.1M |
|
277
VeriSign
VRSN
$26.5B
| $40.2M | 0.09% |
198,402
-49,361
| -20% | -$9.46M |
|
278
Assurant
AIZ
$14.2B
| $39.7M | 0.09% |
317,784
+201,733
| +174% | +$26.9M |
|
279
Aflac
AFL
$61.2B
| $39.6M | 0.09% |
550,850
+209,510
| +61% | +$14M |
|
280
NiSource
NI
$20B
| $39.5M | 0.09% |
1,438,988
+462,075
| +47% | +$12.1M |
|
281
Alaska Air
ALK
$5.27B
| $39.4M | 0.09% |
923,932
-142,723
| -13% | -$6.29M |
|
282
Fair Isaac
FICO
$22.7B
| $39.2M | 0.09% |
66,113
+3,854
| +6% | +$2.03M |
|
283
Dolby
DLB
$5.82B
| $39.1M | 0.09% |
560,900
+105,176
| +23% | +$7.25M |
|
284
SEI Investments
SEIC
$12.6B
| $39.1M | 0.09% |
672,385
+71,887
| +12% | +$4.04M |
|
285
Eversource Energy
ES
$26.8B
| $38.9M | 0.09% |
463,499
+37,225
| +9% | +$2.95M |
|
286
Fidelity National Financial
FNF
$12.9B
| $38.4M | 0.09% |
1,020,855
-123,513
| -11% | -$4.64M |
|
287
Fortune Brands Innovations
FBIN
$5.73B
| $38.3M | 0.09% |
671,882
-29,456
| -4% | -$1.55M |
|
288
Lincoln National
LNC
$8.75B
| $38.2M | 0.09% |
1,251,739
-305,278
| -20% | -$12.1M |
|
289
American Tower
AMT
$78.8B
| $38.1M | 0.09% |
179,823
+12,929
| +8% | +$2.69M |
|
290
Goodyear
GT
$1.74B
| $38M | 0.09% |
3,762,586
+786,354
| +26% | +$8.59M |
|
|
BERY
291
DELISTED
Berry Global Group, Inc.
BERY
| $38M | 0.09% |
686,993
+127,474
| +23% | +$6.25M |
|
292
ACI Worldwide
ACIW
$5.34B
| $37.9M | 0.09% |
1,657,398
-232,201
| -12% | -$5M |
|
293
Organon & Co
OGN
$3.58B
| $37.6M | 0.09% |
1,347,995
+260,445
| +24% | +$6.66M |
|
294
Cintas
CTAS
$81.1B
| $37.5M | 0.09% |
333,360
-28,132
| -8% | -$3.04M |
|
295
Terex
TEX
$7.58B
| $37.4M | 0.09% |
876,585
-64,899
| -7% | -$2.61M |
|
296
Estee Lauder
EL
$31.5B
| $37.3M | 0.09% |
151,557
-17,573
| -10% | -$3.92M |
|
297
Cencora
COR
$62B
| $37.2M | 0.08% |
225,174
+17,568
| +8% | +$2.78M |
|
298
Rollins
ROL
$17.9B
| $37.1M | 0.08% |
1,019,704
+89,432
| +10% | +$3.47M |
|
299
Pinnacle West Capital
PNW
$12B
| $37M | 0.08% |
486,416
+32,635
| +7% | +$2.33M |
|
300
Brown-Forman Class B
BF.B
$12.9B
| $36.9M | 0.08% |
562,725
+114,093
| +25% | +$7.74M |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.